Group 1 - The company has proposed to adjust the annual remuneration for independent directors from 180,000 RMB to 240,000 RMB, which aligns with industry standards and aims to enhance corporate governance [1][2] - The adjustment requires approval from the upcoming extraordinary general meeting of shareholders [1] Group 2 - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure [3][4] - The issuance will comply with relevant laws and regulations and requires approval from regulatory bodies [4][5] - The company is currently discussing the issuance with relevant intermediaries, and specific details are yet to be finalized [4] Group 3 - The company has scheduled the extraordinary general meeting for October 17, 2025, to discuss the proposed H-share issuance and other matters [9][10] - Voting will be conducted through both on-site and online platforms [10][11] Group 4 - The company has appointed Crowe (Hong Kong) CPA Limited as the auditing firm for the H-share issuance [23][24] - The auditing firm has a strong track record and is expected to meet the company's needs for the H-share issuance [27][28] Group 5 - The board of directors has approved several resolutions regarding the H-share issuance, including the types of shares, issuance methods, and fundraising plans [31][34] - The proposed fundraising will be used for drug research and development, overseas commercialization, and working capital [62]

Key Points - Hainan Huatie's shareholder Hu Danfeng has terminated the share reduction plan and plans to increase holdings in the company with an investment of no less than 30 million yuan and no more than 50 million yuan [2] - Yonghe Co. expects a net profit increase of 447.64% to 506.85% year-on-year for Q3 2025, driven by the high demand in the refrigerant industry and product optimization [3] - Delis Co. is planning a change in company control, leading to a suspension of its stock from October 9, 2025 [4] - BYD reported September 2025 sales of 396,300 new energy vehicles, a slight decrease from 419,400 units in the same month last year, while cumulative sales for the year reached 3.26 million units, up 18.64% [5] - Chipone Technology expects Q3 2025 revenue of 1.284 billion yuan, marking a historical high for the company, with a year-on-year increase of 78.77% [7] - Chipone anticipates a significant improvement in profitability for Q3 2025, with new orders expected to reach 1.593 billion yuan, a year-on-year increase of 145.80% [8] - ST Zhengping's stock will be suspended from trading starting October 9, 2025, due to unusual stock price fluctuations [2][28] - Huanxin Cement plans to repurchase shares worth between 32.25 million and 64.5 million yuan [14] - Sichuan Gold won exploration rights for a gold mine in Xinjiang for 510 million yuan, indicating strong geological potential [15]

Core Viewpoint - The trend of A-share companies seeking to list in Hong Kong continues, with a significant number of companies announcing plans to do so in September 2023 [1] Group 1: A-share Companies Going Public in Hong Kong - As of September 30, three A-share listed companies, namely XinNuoWei, Kexing Pharmaceutical, and KOTAI Power, announced plans to list in Hong Kong [1] - In total, 25 A-share listed companies have announced plans to list in Hong Kong since the beginning of September 2023 [1] - As of October 2, there are 76 A-share listed companies that have submitted listing materials to the Hong Kong Stock Exchange and are awaiting hearings [1] Group 2: Industry Distribution - The A-share companies that have submitted applications for listing in Hong Kong cover various industries, including pharmaceuticals, telecommunications, food and beverages, automotive, and machinery [1] - Notable companies from multiple sectors are among those seeking to list in Hong Kong [1]

Core Points - The company has received acceptance for its clinical trial application for GB10 injection, marking a significant step in its innovative drug development process [1][2][3] - GB10 injection is a high-concentration ophthalmic injection developed by the company, targeting age-related macular degeneration and diabetic macular edema [2] - Successful development and potential market launch of GB10 injection could enhance the company's product portfolio and market competitiveness [3] Summary by Sections Application Registration Details - Product Name: GB10 Injection [2] - Application Type: Domestic production drug registration clinical trial [2] - Acceptance Number: CXSL2500841 [2] - Indications: Treatment for neovascular diseases such as age-related macular degeneration (nAMD) and diabetic macular edema (DME) [2] - Dosage Form: Injection [2] - Product Overview: GB10 injection is a dual-target antibody with global intellectual property rights, showing efficacy in preclinical studies comparable to international competitors [2] Impact on the Company - The acceptance of the clinical trial application is a crucial milestone in the company's dual-antibody research strategy, indicating progress in its innovative drug development [3] - If successful, the drug could meet market demands with a more diverse product offering, thereby enhancing the company's competitive position [3]

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [4] - Bee Assistant plans to raise no more than 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [5] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Three squirrels have received approval from the China Securities Regulatory Commission for H-share issuance, with plans to issue up to 81.5483 million shares [7] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [8] Group 2 - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind, solar, and energy storage [9] - Sains plans to invest no more than 300 million yuan in the expansion of its selection agent project [10] Group 3 - Hunan YN reports no significant changes in its internal and external operating environment [11] - Electric Power Investment has had its major asset replacement review suspended by the Shenzhen Stock Exchange due to expired financial documents [12] - Guanzhong Ecological is in the planning stage for acquiring a 51% stake in Hangzhou Actuary [13][14] Group 4 - Aima Technology's subsidiary is transferring production capacity and ceasing operations due to strategic adjustments [17] - Fosun Pharma's subsidiary has received approval for clinical trials of a new drug [18] - SAIC Group's subsidiary plans to invest 666 million yuan in the restructuring of SAIC Hongyan [19] Group 5 - Hanwei Technology plans to sell 65% of Hanwei Zhiyuan for approximately 440 million yuan [20] - Xingtong Co. has been awarded new capacity for coastal inter-provincial bulk liquid hazardous goods transportation [21][22] Group 6 - EVE Battery Investment received a cash dividend of 375 million HKD from its associate company [23] - Shanmei International's chairman has resigned due to work changes [24] - Weiye Co.'s chairman has resigned for personal reasons [25] Group 7 - Jiao Da Sino's chairman has been placed under detention [26] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [27][28] - *ST Zhengping's stock has been suspended for investigation due to abnormal price fluctuations [29] Group 8 - Zhenray Technology's chairman has had detention measures lifted [30] - Shiming Technology's chairman has had detention measures changed to a warning [31] - Nanxin Pharmaceutical is under investigation by the CSRC for suspected violations in annual report disclosures [32] Group 9 - Daqian Ecology's shareholder plans to reduce holdings by up to 3% [33] - Rundar Medical's shareholders plan to reduce holdings by up to 2.99% [34][35] - Saili Medical's shareholder plans to reduce holdings by up to 2% [36] Group 10 - Huaxin Environmental plans to repurchase shares for 40 to 80 million yuan [37] - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [38] - Zhongwu Drone has signed a significant contract worth 615 million yuan for drone systems [39]

Core Viewpoint - Company plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence and competitiveness [2] Group 1 - Company aims to deepen its "innovation + internationalization" strategy to accelerate overseas business development [2] - The move is intended to improve the company's overall competitiveness and international brand image [2] - Company seeks to leverage international capital market resources and mechanisms to optimize its capital structure and diversify financing channels [2]

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [2] - Bee Assistant plans to raise up to 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [3] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] Group 2 - Three squirrels received approval from the China Securities Regulatory Commission for H-share issuance, planning to issue up to 81.5483 million shares [5] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [6] - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind and solar energy [7] Group 3 - Sainz's subsidiary plans to invest up to 300 million yuan in the expansion of selection and extraction agents [8] - Hunan YN reported no significant changes in its internal and external operating environment [9] - Electric Power Investment plans to restructure assets and has received a notice from the Shenzhen Stock Exchange to suspend review [10] Group 4 - Guanzhong Ecology is in the planning stage to acquire 51% of Hangzhou Actuary [11] - Aima Technology announced the transfer and suspension of production capacity at its subsidiary in Guangdong [12] - Fosun Pharma's subsidiary received approval for clinical trials of a new drug [13] Group 5 - EVE Battery Investment received a cash dividend of 375 million HKD from its indirect associate, Simoer International [14] - Shanmei International announced a change in its board leadership due to personnel changes [15] - Weiye Co. announced the resignation of its chairman for personal reasons [16] Group 6 - Jiaoda Sinuo's chairman is under detention, and the company has appointed a new acting chairman [17] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [18] - ST Zhengping's stock price has seen an abnormal increase, leading to a suspension for investigation [19] Group 7 - Daqian Ecology's shareholder plans to reduce its stake by up to 3% [20] - Rundat Medical's shareholders plan to collectively reduce their stake by up to 2.99% [21] - Seli Medical's shareholder plans to reduce its stake by up to 2% [22] Group 8 - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [23] - Zhongwu Drone signed a significant contract worth 615 million yuan for drone systems [24]

Core Viewpoint - The company, Sinovac Biotech Ltd. (科兴制药), aims to enhance its strategic layout of "innovation + internationalization" by accelerating overseas business development and improving its overall competitiveness and international brand image through the issuance of H-shares and listing on the Hong Kong Stock Exchange [1] Group 1 - The company plans to issue H-shares to optimize its capital structure [1] - The move is intended to leverage the advantages of international capital markets for diversified financing channels [1] - The initiative is part of the company's strategy to deepen its presence in the global market [1]

科兴生物制药股份有限公司 董事会审计委员会工作细则 （H 股发行上市后适用） 2025 年 9 月 | 附则 9 | | --- | | 第六章 | 科兴生物制药股份有限公司 董事会审计委员会工作细则 第一章 总 则 第一条 为强化科兴生物制药股份有限公司（以下简称"公司"）董事会决策功能，健全 董事会的审计评价和监督机制，确保董事会对经理层的有效监督，进一步完善公司治理 结构，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司治理 准则》《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》《香港联合交易所有限公司证券上市规则》（以下简称"《联交 所上市规则》"）、《科兴生物制药股份有限公司章程》（以下简称"《公司章程》"） 及其他有关规定，公司设立董事会审计委员会，并制定本工作细则。 第二条 董事会审计委员会是董事会下设的专门工作机构，协助董事会开展相关工作， 向董事会报告工作并对董事会负责，以及与内外部审计的独立沟通、监督和核查工作。 第三条 审计委员会根据《公司章程》的规定和本工作细则的职责范围履行职责，独立 工作不受公司其他部门或个人的干预。 ...

科兴生物制药股份有限公司 董事会提名委员会工作细则 （H 股发行上市后适用） 2025 年 9 月 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 人员组成 1 | | | 第三章 | 职责权限 2 | | | 第四章 | 决策程序 3 | | | 第五章 | 议事规则 3 | | | 第六章 | 附则 | 5 | 科兴生物制药股份有限公司 董事会提名委员会工作细则 第一章 总则 第一条 为规范科兴生物制药股份有限公司（以下简称"公司"）董事及高级管理 人员的产生，优化董事会成员组成，完善公司治理结构，根据《中华人民共和国 公司法》《上市公司治理准则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《香港联合交易所有限公司证券上市规则》（以下简称"《联 交所上市规则》"）、《科兴生物制药股份有限公司章程》（以下简称"《公司章 程》"）及其他有关规定，公司设立董事会提名委员会，并制定本工作细则。 第二条 董事会提名委员会是董事会设立的专门工作机构，主要负责对公司董事 和高级管理人员的人选、选择标准和程序进行选择并提出建议。 第三条 本细则所称高级管理人 ...